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Tumour cells of extramammary Paget's disease do not
show either p53 mutation or allelic loss at several
selected loci implicated in other cancers
M Takata, N Hatta and K Takehara
Department of Dermatology, Kanazawa University School of Medicine, 13-1 Takara-machi, Kanazawa 920, Japan
Summary Extramammary Paget's disease is a particular form of skin cancer of unknown histogenesis. To look for the genetic defects
underlying the pathogenesis of this tumour, we have examined loss of heterozygosity (LOH), p53 and human papillomavirus (HPV) status,
and the expression of c-erbB-2 and bcl-2 proteins in 14 cases. Unexpectedly, no LOH was detected at several loci commonly lost in other
human cancers (namely 3p, 9p, 9q, 13q, 16q, 17p, and 17q) in 12 tumours examined. Altered p53 protein expression was entirely or mostly
negative in all 14 cases. Direct sequencing of exons 5-8 of the p53 gene in eight cases revealed no mutation. Polymerase chain reaction
amplification of the Ll gene of human papillomavirus (HPV) did not detect the virus that could inactivate p53 and retinoblastoma tumour-
suppressor gene products. As expected, c-erbB-2 proto-oncogene protein was overexpressed in six cases. The expression of bcl-2 was
negative in all cases. The results presented in this study suggest that molecular events underlying extramammary Paget's disease differfrom
those of other common epithelial malignancies and that tumour-suppressor genes located in chromosome regions not examined in this study
may be important.
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Paget's disease presents as a slowly enlarging reddish patch
affecting the nipple, anogenital area or other apocrine gland-
bearing sites and is characterized histologically by the presence of
a population oflarge neoplastic cells with pale-staining cytoplasm
(Paget's cells) within the epidermis. The mammary form of the
disease is usually associated withunderlying ductal carcinoma and
is regarded as an epidermal manifestation of a breast carcinoma,
although the precise site of origin and mode of migration of
Paget's cells to the epidermis is unclear (Toker, 1961). The patho-
genesis and histogenesis of the extramammary form, by contrast,
are far more controversial, because most of the cases have no
underlying carcinomas and the origin ofPaget's cells is unknown
(Hart and Millman, 1977; Jones et al, 1979). A variety ofcell types
have been proposed as the progenitors of extramammary Paget's
cells, including pluripotential germinative epidermal cells
(Murrell Jr and McMullan, 1962; Jones et al, 1979), and cells of
both eccrine and apocrine sweat glands (Demopoulos, 1971; Lee
et al, 1977; Roth et al, 1977; Mazoujian et al, 1984; Hamm et al,
1986). Furthermore, extramammary Paget's disease may arise
multicentrically within the anogenital area (Gunn and Gallager,
1980) or even in distant anatomical sites known as 'triple' extra-
mammary Paget's disease in which genitalia and both sides of
axillae are affected atthe same time (Kawatsu and Miki, 1971). As
extramammary Paget's disease is a neoplasm with potential
metastatic spread, it is likely to have defects in putative oncogenes
and tumour-suppressor genes as is the case with other human
cancers. However, very little is known about thegenetic abnormality
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underlying extramammary Paget's disease. There have been only a
few reports showing overexpression of ras p21 (Mori et al, 1990)
and c-erbB-2 proto-oncogene products (Keatings et al, 1990;
Meissner et al, 1990; Wolber et al, 1991; Nishi et al, 1994), and
altered expression ofp53 tumour-suppressor protein (Wienecke et
al, 1994; Nakamura et al, 1995). Because of its particular biolog-
ical properties, we were interested in examining genetic changes in
extramammary Paget's disease.
In human epithelial neoplasms, defects in tumour-suppressor
genes are common (Fearon and Vogelstein, 1990; Yokota and
Sugimura, 1993). Although tumour-suppressor genes may be inac-
tivated in a number of different ways, a particularly common
mechanism is mutation of one allele followed by loss of the
remaining allele (Ponder, 1988). To look for defects in tumour-
suppressor genes underlying extramammary Paget's disease, we
performed polymerase chain reaction (PCR)-based microsatellite
loss of heterozygosity (LOH) assays for several selected loci that
map to chromosome regions harbouring important tumour-
suppressor genes such as p53 (Nigro et al, 1989) and retinoblas-
toma (Rb) (Horowitz et al, 1990) and which are commonly deleted
in other human cancers (Ponder, 1988; Yokota and Sugimura,
1993). Furthermore, the p53 status was examined by immunohis-
tochemistry and direct sequencing of exons 5-8 of the p53 gene.
The presence or integration of human papillomaviruses (HPV)
into tumour DNA was also investigated, because the disease
mainly affects anogenital skin, where HPV infections are not
uncommon (DeVita et al, 1987), and because E6 and E7 oncopro-
teins encoded by several types of HPV are known to bind to p53
and Rb proteins and to inactivate their tumour-suppressor function
(Dyson et al, 1989; Werness et al, 1990). Finally, the expression of
c-erbB-2 and bcl-2 proto-oncogene products was evaluated by
immunohistochemistry.
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Table 1 Molecular genetic and immunohistochemical studies of extramammary Paget's disease
Loss of heterozygositya Immunohistochemistryb
Case no. Age/sex Type of Lymph node PCR for
carcinoma metastasis 3p 9p 9q 13q 16q 17p 17q p53genea p53 erbB-2 bcl-2 HPV
1 63/M Invasive Positive 0 0 NI 0 0 0 NI NE +* + - -
2 86/M In situ Negative 0 0 0 0 0 0 NI NE
3 48/M Invasive Negative 0 0 0 0 0 0 NP NE - +
4 78/M Invasive Negative 0 0 0 NI 0 0 0 NE - +
5 69/M Invasive Positive 0 NI 0 0 0 0 0 NE +*
6 70/M Invasive Positive NI NI NI NP 0 0 0 NE - +
7 76/M Invasive Positive 0 0 0 0 NI 0 0 wild-type - +
8 72/M In situ Negative NI NI 0 0 0 0 0 wild-type -
9 72/F In situ Negative 0 NI NI 0 0 0 NI wild-type -
10 78/M Invasive Positive 0 0 0 0 0 0 0 wild-type - +
11 76/M Invasive Negative 0 NI 0 0 0 NI 0 wild-type +*
12 58/M Invasive Negative 0 NI 0 0 0 NI NI wild-type
13 70/F In situ Negative NE NE NE NE NE NE NE wild-type
14 71/M In situ Negative NE NE NE NE NE NE NE wild-type -
a Loss of heterozygosity; 0, no loss of heterozygosity; NI, homozygous; NP, no product; -, not examined. b* positive cells less than 5%; C-erbB-2
immunostaining was recorded as + when more than 80% of Paget's cells showed distinct membrane staining.
MATERIALS AND METHODS
Selection of clinical samples
A total of26 cases ofextramammary Paget's disease were initially
retrieved from the pathology files of the Department of
Dermatology at Kanazawa University Hospital. Fresh-frozen
tissues had been stored in eight cases and only paraffin-embedded
tissue blocks were available in the remaining 18 cases. After
reviewing pathology slides, eight cases in which isolated Paget's
cells were present only within the epidermis were excluded
because they were unsuitable for microdissection. Paraffin-
embedded sections (15,m) or frozen sections (6 jm) of the
remaining 18 tumours were mounted on to glass slides and
microdissected using a fine needle point on an inverted micro-
scope. Tumour DNA was isolated according to standard methods
by proteinase K digestion and phenol-chloroform extraction as
described previously (Takata et al, 1996). Control DNA was
obtained from either peripheral blood or normal adjacent skin of
the corresponding patients. An additional four cases were further
eliminated at this stage because of the poor quality of tumour
and/or control DNA. The remaining 14 cases were subjected to
further genetic and immunohistochemical analyses. The patients
comprised 12 men and two women. All the male patients had
lesions typical of extramammary Paget's disease on genital skin
including scrotum and penis. The female patients had a vulvar or a
pubic lesion. None of the cases was associated with underlying
genitourinary orgastrointestinal malignancies. Histologically, nine
tumours had nests or clusters of Paget's cells invading into the
dermis and five patients had histologically documented inguinal
lymph node metastases (Table 1).
Microsatellite-PCR loss of heterozygosity analysis
LOH was analysed in 12 cases by PCR amplification of
microsatellite polymorphism as described previously (Takata et al,
1996). Approximately 100 ng of template DNA was amplified
with 1 pmol of each oligonucleotide primer, one of which was
end-labelled with [32P]ATP, 0.2 mm of each deoxynucleotide and
0.5 unit of Taq DNA polymerase (Promega, Madison, WI) in a
final volume of 10,l. The microsatellite oligonucleotide primers
used were D3S1293 (3p), D9S171 (9p), D9S197 (9q), D13S155
(13q), D16S413 (16q), D17S796 (17p), and D17S785 (17q), all
obtained from Research Genetics (Huntsville, AL, USA). PCR
products were separated through 6% acrylamide gels, which were
subsequently dried and exposed to Fuji XR films overnight at
-80°C. LOH was scored visually by two observers and a signifi-
cant reduction in the signal intensity of one of two tumour alleles
was recorded as LOH.
Direct sequencing of the p53gene
Direct sequencing ofthep53 gene was carried out in eight cases in
which enough DNA was available. Exons 5-8 ofp53 gene were
amplified by PCR with standard condition using oligonucleotide
primers as previously described (Campbell et al, 1993).
Amplification was confirmed by 1% agarose gel electrophoresis,
and the PCR products were purified with a DNA affinity spin
column (Wizard PCR Preps, Promega, Madison, WI, USA). All
purified samples were directly sequenced by automated
sequencing with fluorescently labelled dideoxy chain-terminating
nucleotides and Taq DNA polymerase using Dye Terminator
Cycle Sequencing Ready Reaction Kit (Perkin Elmer, Foster City,
CA, USA). The products were analysed on an Applied Biosystems
Model 373A Automated DNA sequencing machine.
Detection of HPV DNA
HPV DNA sequences were detected by PCR amplification using
a primer pair (HPV-1003 and HPV-1004) for the conserved
sequence of the LI gene of HPV-6, -11, -16, -18, -31, and -33
(Snijders et al, 1990), purchased from Maxim Biotech (San
Francisco, CA, USA). The PCR mixtures contained tumour DNA,
0.1 mm of each deoxynucleotide and 1 unit of Taq DNA poly-
merase (Promega, Madison, WI, USA) as well as the primers and
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Figure 1 Representative autoradiograph of PCR-based microsatellite LOH
analysis in patients with extramammary Paget's disease. Lanes 1-9 show
PCR product of microsatellite polymorphism Dl3S155 (chromosome arm
13q) from normal (C) and tumour (T) DNA in four patients (cases 7, 8, 9 and
10). In case 7, tumour DNA was isolated from two separate sites within the
primary lesion. All lanes show two distinct alleles, indicating no LOH
PCR buffer supplied by the manufacturer. PCR conditions were as
follows: 94°C for 3 min (1 cycle), 94°C for 1 min, 40°C for 1 min,
72°C for 1 min (35 cycles) and 720C for 10 min (1 cycle). As posi-
tive controls HPV-18 DNA (HPV-4006) (Maxim Biotech, San
Francisco, CA, USA) and HeLa cell DNA were included in every
PCR. A total of5 gl PCR product was analysed by 1% agarose gel
electrophoresis.
Immunohistochemistry
Immunohistochemical staining for p53, bcl-2 and C-erbB-2 was
performed on 4-im paraffin sections using the biotin-streptavi-
dine-peroxidase method. Before immunostaining forp53 and bcl-2,
antigen retrieval was performed by immersing slides in sodium
citrate buffer (pH 6.0) and heating for 10 min in a conventional
microwave oven. After blocking endogenous peroxidase with 3%
hydrogen peroxide in methanol, the sections were incubated with
primary antibody at 40C overnight followed by sequential 30-min
incubations with biotinylated rabbit anti-mouse immunoglobulins
and a streptavidin-biotin-peroxidase complex (Histofine Kit,
Nichirei, Tokyo, Japan). Primary antibodies used were anti-p53,
D07 (1/100) (Novocastra, Newcastle, UK), anti-bcl-2, Ab-l
(1/100) (Oncogene Science, Cambridge, MA, USA) and anti-c-
erbB-2 (1/40) (Novocastra, Newcastle, UK). Primary antibodies
were replaced by phosphate-buffered saline in the negative
controls. Diaminobenzidine was used as the peroxidase substrate
and the sections were counterstained with methylgreen. Only cases
exhibiting distinct membrane staining in more than 80% ofPaget's
cells were identified as positive for c-erbB-2 overexpression
(Barbareschi et al, 1992).
RESULTS
The results of molecular genetic and immunohistochemical
analyses in 14 cases are shown in Table 1. In LOH analyses, a total
of 63 loci were heterozygous and 21 were uninformative (19 loci
were homozygous and the other two gave no PCR products).
Unexpectedly, no LOH was detected at any of the 63 informative
R
Figure 2 Immunohistochemical analysis of p53 protein (A) and c-erb-B2 (B)
expression in extramammary Paget's disease. Note scattered nuclear
staining for p53 protein (case 1) and strong membrane staining for c-erb-B2
(case 3). Scale bar = 50 gm
loci (Fig. 1). Altered p53 protein expression was entirely negative
in 11 cases, while the remaining three tumours had occasional
nuclear staining in less than 5% of Paget's cells (Fig. 2A),
although nuclear staining was weak or faint in cases 5 and 11.
Direct sequencing of exons 5-8 of the p53 gene in eight cases
revealed no mutation. PCR amplification of the HPV LI gene
failed to detect HPV DNA in all tumours whereas control HPV-18
DNA and HeLa cell DNA consistently gave specific 550-bp prod-
ucts. Overexpression ofc-erbB-2 protein was observed in 6 out of
14 tumours (Fig. 2B). Expression ofbcl-2 was entirely negative in
all cases.
DISCUSSION
We selected 12 specimens of extramammary Paget's disease suit-
able for microdissection and conducted PCR-based microsatellite
LOH analyses. The analyses were carried out using seven
microsatellite polymorphisms on chromosome arms 3p, 9p, 9q,
13q, 16q, 17p and 17q that are commonly deleted in other malig-
nant epithelial tumours including non-melanoma skin cancers
(Ponder, 1988; Yokota and Sugimura, 1993; Quinn et al, 1994).
The three microsatellite markers used in this study, D17S796,
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D9S171 and D13S155, map to l7pl3, 9p2l and 13ql4 respec-
tively, where known important tumour-suppressor genes p53, p16
and Rb reside (Nigro et al, 1989; Horowitz et al, 1990; Kamb et al,
1994). In view ofthe phenotypical similarity ofextramammary to
mammary Paget's disease, which is essentially a skin manifesta-
tion of underlying breast carcinoma (Tocker, 1961), selected loci
included several chromosome regions frequently deleted in breast
carcinomas (e.g. 3p, 13q, 16q, 17p and 17q), although chromo-
somes 1, 6, 8, 11 and 22, which are also frequently lost, were not
examined (Devilee and Comelisse, 1994). The result that no LOH
was detected at any of the seven loci commonly lost in a wide
range of epithelial tumours in any of the 12 tumours is perhaps
surprising. Histological and ultrastructural observations show that
Paget's cells are adenocarcinoma cells (Roth et al, 1977; Jones et
al, 1979; Ordonez et al, 1987) and most adenocarcinomas do lose
these chromosome arms (Ponder, 1988; Fearon and Vogelstein,
1990; Yokota and Sugimura, 1993). There are a number offactors
that need to be considered in interpreting this result. First, LOH
could have been missed because of the presence ofcontaminating
non-tumour cells such as keratinocytes, appendageal epithelia and
interstitial cells in tumour samples. However, this seems unlikely
because we selected tumours that had large nests of Paget's cells
within the epidermis and/or dermis that enabled us to dissect our
relatively pure tumour samples (tumour cells more than 70-80%).
We have previously detected multiple LOH in smaller lesions such
as actinic keratoses (Rehman et al, 1996). Second, small deletions
are likely to have been missed by the present study, in which only
one microsatellite locus for one chromosome arm was examined.
Third, the inactivation of tumour-suppressor genes may have
occurred by mechanisms other than mutation followed by wild-
type allelic loss (Fearon and Vogelstein, 1990).
To examine for mutations ofp53 gene, we initially investigated
p53 protein expression by immunohistochemistry. Missense muta-
tions ofp53 gene stabilize the protein, thus making it amenable to
detection by immunohistochemistry, whereas in normal cells wild-
type protein is undetectable (Iggo et al, 1990). Consistent with a
previous study using the same D07 antibody (Kanitakis et al,
1993), p53 expression was mostly negative in our cases of extra-
mammary Paget's disease, suggesting that the absence of p53
mutations, although nonsense or frameshift mutations would not
produce stabilized p53 protein (Greenblatt et al, 1994). The
absence of p53 mutations was further confirmed by direct
sequencing of exons 5-8 of the p53 gene in eight cases, all of
which showed wild-type sequence. Although recent studies
showed that the nearly 20% of mutation of thep53 gene occurred
outside exons 5-8 (Greenblatt et al, 1994; Casey et al, 1996), our
results strongly suggest thatp53 mutations are not operative in the
evolution ofextramammary Paget's disease.
The absence ofp53 mutations and detectable LOH on chromo-
some arms 17p and 13q prompted us to investigate the participa-
tion of HPV in the pathogenesis ofextramammary Paget's disease
because this virus is frequently found in anogenital tumours
(DeVita et al, 1987), and because the E6 and E7 oncoproteins
encoded by high-risk HPVs (e.g. HPV-16, and -18) bind to p53
and Rb proteins respectively and inactivate theirgrowth-inhibitory
effects (Dyson et al, 1989; Wemess et al, 1990). In cervical carci-
noma, in which HPV is frequently present, low frequency of both
p53 mutation and allelic loss at loci implicated in other common
malignancies has been reported (Scheffner et al, 1991; Busby-
Earle et al, 1993). Thus, we looked for HPV DNA in our cases by
PCR using consensus primers for HPV LI gene (Snijders et al,
1990). However, in keeping with the previous report using in situ
hybridization (Snow et al, 1992), we could not detect HPV
genome in any tumours examined. Therefore, the involvement of
HPV in the tumorigenesis ofextramammary Paget's disease seems
unlikely, although there remains a possibility that a virus may play
a 'hit and run' role in tumour pathogenesis (Campo et al, 1985).
Finally, we examined the expression ofc-erbB-2 protein, a proto-
oncogene product reported to be overexpressed in a subset ofextra-
mammary Paget's disease (Keatings et al, 1990; Meissner et al,
1990; Wolberetal, 1991; Nishi etal, 1994), andbcl-2protein, which
belongs to a group of proto-oncogenes that prolong the survival of
cells by blocking apoptosis (Lu et al, 1996). As expected, overex-
pression ofc-erbB-2 protein, which reflects c-erbB-2 gene amplifi-
cation, was observed in 43% ofthe tumours. The higher prevalence
of c-erbB-2 overexpression in our series compared with previous
studies (Keatings et al, 1990; Meissner et al, 1990; Wolber et al,
1991; Nishi et al, 1994) may be explained by case selection bias
because 9 out of 14 cases investigated in this study were invasive
carcinomas, in which c-erbB-2 overexpression is generally more
prominent than in in situ lesions (Nishi et al, 1994). Expression of
bcl-2 was entirely negative in all cases, suggesting that activation of
bcl-2 proto-oncogene does not play a role.
Unexpectedly, this study did not detect any allelic loss at several
selected loci implicated in other common epithelial malignancies
including non-melanoma skin cancers and breast carcinoma in
extramammary Paget's disease. No mutations of the p53 gene
were detected, and the participation ofHPV infection, which could
alternatively inactivate p53 and Rb tumour suppressor genes by
mechanisms other than mutation followed by LOH, was unlikely.
These results suggest that the underlying genetic defects in extra-
mammary Paget's disease are different from those in other
common epithelial malignancies, and that tumour-suppressor
genes located in chromosome regions not examined in this study
may be important. It is worth examining LOH patterns in sweat
gland carcinomas because of the suspected relationship between
extramammary Paget's disease and eccrine or apocrine sweat
glands (Demopoulos, 1971; Lee et al, 1977; Roth et al, 1977;
Mazoujian et al, 1984; Hamm et al, 1986). We previously showed
isolated LOH at 17q in an eccrine porocarcinoma (Takata et al,
1996). LOH assays of additional cases of sweat gland carcinomas
are now underway in our laboratory. Further molecular genetic
studies will provide new insights into the controversial histo-
genesis and peculiar biological behaviour of this particular skin
cancer.
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